Integra LifeSciences Q3 2025: Solid Growth, Zero Mention of Ransomware Fallout
Summary: Five days after the November 13 Clop ransomware attack, Integra LifeSciences’ latest financial recap (published November 16) reports Q3 revenue of $402.1 million — up 5.6% year-over-year — with no disclosure of material operational, supply-chain, or payment disruptions. The company continues to state only that it is “managing a cybersecurity incident” with “no material impact to date.” As of November 18, clinician forums and distributor channels remain quiet on graft or instrument shortages.
Key Highlights:
- Q3 Revenue: $402.1M (+5.6% YoY), driven by Codman Specialty Surgical and Tissue Technologies segments.
- Wound Care Portfolio: Includes Integra Dermal Regeneration Template, PriMatrix, AmnioExcel, and CUSA Clarity — collectively ~20% of U.S. advanced wound procedures.
- Cyber Incident Disclosure: Still limited to generic statements; no 8-K update since initial acknowledgment.
- Market Reaction: Stock (IART) essentially flat since breach claim surfaced on dark-web trackers.
- Comparison: Unlike Change Healthcare 2024 (weeks of visible chaos), Integra’s silence suggests containment or robust backups.
Keywords: Integra LifeSciences, ransomware, Clop, Q3 2025, supply chain, provider payments, IART
Editor’s Note: M-Med USA has ample supplies of total contact casting kits to help mitigate any disruptions in offloading solutions for DFUs. Contact them for immediate availability and support.